Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares OutstandingShares Outstanding
Ratios

Lyra Therapeutics (LYRA) Other Gross PP&E Adjustments (2021 - 2025)

Lyra Therapeutics has reported Other Gross PP&E Adjustments over the past 5 years, most recently at -$12.3 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$12.3 million for Q4 2025, up 20.31% from a year ago — trailing twelve months through Dec 2025 was -$12.3 million (up 20.31% YoY), and the annual figure for FY2025 was -$12.3 million, up 20.31%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$12.3 million at Lyra Therapeutics, down from -$12.0 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for LYRA hit a ceiling of $7.0 million in Q2 2022 and a floor of -$45.6 million in Q1 2024.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$3.9 million (2023), compared with a mean of -$6.9 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 91.88% in 2022 and later tumbled 2400.05% in 2024.
  • Lyra Therapeutics' Other Gross PP&E Adjustments stood at $6.2 million in 2021, then crashed by 53.08% to $2.9 million in 2022, then plummeted by 1148.67% to -$30.4 million in 2023, then soared by 49.17% to -$15.5 million in 2024, then rose by 20.31% to -$12.3 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$12.3 million (Q4 2025), -$12.0 million (Q3 2025), and -$12.9 million (Q2 2025) per Business Quant data.